Agilux Laboratories has expanded its in vivo pharmacokinetics services, increasing its capacity and volume aimed at maintaining fast study starts. Agilux has more than doubled its dedicated vivarium space, increasing all in vivo services with potential for additional species and genders. The company is now able to ramp up to utilize 50% of the new space with additional capacity available to clients.
“Investing in the current and future growth of this facility and our in vivo capabilities ensures that we can continue to service existing and prospective clients in the fastest, most flexible and efficient manner possible,” said Jim Jersey, president and chief executive officer. “The iterative nature of in vivo pharmacokinetic screening requires rapid cycle times with turn-on-a-dime changes in priorities. This important expansion will help us support our clients’ demands, while allowing for the continuance of rapid study initiations that are a hallmark of Agilux’s in vivo capabilities.”
Agilux Labs Expands Pharmacokinetics Services
Published December 4, 2013
blog comments powered by Disqus